CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.
about
Novel immunotherapeutic approaches to the treatment of urothelial carcinomaEvolving immunotherapy strategies in urothelial cancerOptimizing dendritic cell-based approaches for cancer immunotherapyCurrent and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.Trial Watch: Experimental Toll-like receptor agonists for cancer therapyAdvanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches.Nonmuscle invasive bladder cancer: a primer on immunotherapy.Targeting CLEC9A delivers antigen to human CD141(+) DC for CD4(+) and CD8(+)T cell recognitionNovel molecular targets for the therapy of urothelial carcinoma.Targeting antigens to dendritic cell receptors for vaccine developmentDendritic cell-targeted vaccines.Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccineFuture directions in bladder cancer immunotherapy: towards adaptive immunity.Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer.CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses.Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccinesNew therapies in nonmuscle invasive bladder cancer treatment.Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.Investigation of factors influencing the immunogenicity of hCG as a potential cancer vaccine.Significant Immunohistochemical Expression of Human Chorionic Gonadotropin in High-Grade Osteosarcoma is Rare, but May Be Associated with Clinically Elevated Serum LevelsVaccines in clinical trials: cancer
P2860
Q26744347-91280686-2547-46D4-9859-0883626437BEQ26823557-4D5F3804-E3FB-47AD-AD48-81E124691011Q34637535-F7ABE76B-0582-4D7B-8DC9-B53C856BEC1DQ34993621-1BB3B264-FECA-48C2-AAC2-6A07D87E540BQ36194849-1709C075-9999-4BFF-AFED-A532E0F437CEQ36589753-B18A5DEA-0ACD-4889-8601-5CE062E1E489Q37094072-7BDA2B0D-FE12-4D91-A96B-E408B2A42489Q37277188-52F71498-11AF-4300-95EF-F0DB0E34CFE3Q38003195-72626402-7E15-4815-AEB9-906F80D0929EQ38162446-0921B16C-A7E0-4986-B9B8-0B1E4F961CF8Q38218671-C24D3E35-536A-416E-98BB-7B274432EFECQ38303372-FBB0A886-E332-47F6-9E62-6AFB65FD637AQ38727522-5BD5D7A5-D618-4FD4-AA4A-118F8A314442Q38823147-D3E8BE62-9670-4354-913A-464C5A8CAC9FQ39448429-B5464B40-0680-4023-AFB8-5A7BCD809C4DQ39448911-C7673B91-1057-4EBF-8181-75BD4663B60EQ49519778-4D0DC8F3-CDC6-48A7-9232-5C1DEB688D88Q50457532-BACF55C2-5517-4151-A332-4B1ED3EE04CFQ52722908-1A140525-C417-4D89-A4D4-BDF085235B15Q57505097-8CA41600-E036-4B6E-8019-5B5A333A83A6Q57594208-A3CE2303-EAEF-4F84-89A4-5C6091607804
P2860
CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.
@en
CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.
@nl
type
label
CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.
@en
CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.
@nl
prefLabel
CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.
@en
CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.
@nl
P2093
P2860
P356
P1476
CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer
@en
P2093
Deborah A Bradley
Jennifer A Green
Michael A Morse
Robert J Laliberte
Thomas A Davis
Tibor Keler
P2860
P304
P356
10.1586/ERV.11.20
P577
2011-06-01T00:00:00Z